Mozobil (Plerixafor)

Name: Mozobil
Brand: Sanofi Aventis
SKU: 7601
Availability: InStock

Type

Product

Manufacturer

Country

Dosage

Qty-Price (USD)

Type:

Product: Mozobil 1.2 ml Vial

Manufacturer: Sanofi Aventis

Country: Canada

Dosage: 20 mg/ml

Qty-Price (USD):

Generic Equivalent of Mozobil

Type

Product

Manufacturer

Country

Dosage

Qty-Price (USD)

There is no generic product of Mozobil.

Mozobil Information

Mozobil at CanadaPharmacyOnline.com

The manufacturer of brand-name Mozobil (plerixafor) is Sanofi-Aventis. It is available in many countries worldwide, including Canada.

The generic plerixafor is currently unavailable (at this pharmacy).

Dosage:

Mozobil (plerixafor) is available as a subcutaneous (under-the-skin) injection solution:
• Injection: 20 mg/mL in a 1.2 mL single-dose vial.

Dosage is individualized. The standard adult dose is 0.24 mg/kg of actual body weight administered subcutaneously once daily. For adults weighing 83 kg or less, a fixed dose of 20 mg may be prescribed.

Usage:

Mozobil (plerixafor) is a CXCR4 chemokine receptor antagonist indicated in combination with granulocyte colony-stimulating factor (G-CSF) to mobilize hematopoietic stem cells into the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin lymphoma (NHL) or multiple myeloma. It is used specifically in patients who are 'poor mobilizers' — those who have not collected enough stem cells with G-CSF alone to proceed to transplantation.

Mechanism of Action
Plerixafor blocks CXCR4 (C-X-C chemokine receptor type 4), a receptor found on the surface of hematopoietic stem cells (HSCs). Under normal conditions, HSCs are retained in the bone marrow because CXCR4 binds to its natural ligand, CXCL12 (also called SDF-1), which anchors HSCs to the bone marrow stroma. By blocking CXCR4, plerixafor disrupts this anchoring interaction, releasing HSCs from the bone marrow and allowing them to enter the peripheral blood (mobilization). This mobilized blood is then collected by apheresis and stored for later transplantation back to the patient after high-dose chemotherapy. When used with G-CSF, plerixafor provides synergistic stem cell mobilization — particularly in patients in whom G-CSF alone is insufficient.

Mozobil is administered exclusively by a healthcare professional in a specialized clinical environment (such as an oncology clinic or hospital transplant unit) where patients can be monitored for allergic reactions and proceed directly to stem cell collection (apheresis). It is not a medication intended for self-administration or home use. For complete information, please refer to the Product Monograph.

The information below summarizes some, but not all, potential side effects, risks, and interactions. Before starting Mozobil, it is essential to discuss all possible side effects, risks, and interactions with your doctor or pharmacist.

Side Effects:

The information below outlines potential side effects of Mozobil (plerixafor). It is not an exhaustive list, and individual reactions can vary.

Common side effects: These are common side effects of Mozobil; other side effects are possible. Contact your doctor promptly if any side effects are persistent, worsening, or concerning.
• Diarrhea, nausea, or vomiting
• Fatigue
• Injection site reactions (redness, itching, or pain at the injection site)
• Musculoskeletal pain or discomfort

Serious Side Effects: Seek immediate medical attention or call emergency services if you experience any of the following symptoms:
• Anaphylaxis or Severe Allergic Reaction: Hives, swelling, difficulty breathing, or rapid drop in blood pressure. Severe hypersensitivity reactions have been reported with plerixafor.
• Spleen Enlargement or Rupture: Sudden left upper abdominal or shoulder pain. Plerixafor, when used with G-CSF, may cause splenic enlargement; splenic rupture has been reported rarely with G-CSF alone. Seek emergency care immediately if suspected.
• Tumor Cell Mobilization: In patients with leukemia or other hematological malignancies with circulating tumor cells, plerixafor could theoretically mobilize them into the bloodstream.

Contraindications:

Do not take Mozobil/plerixafor if:
• Allergies: Known hypersensitivity to plerixafor or any ingredient in the formulation.

Tell your doctor about all of your medical conditions, past and present, before starting Mozobil. This is crucial as certain conditions affect the drug's safety. The following conditions are NOT absolute contraindications, but rather critical clinical precautions that require close monitoring or dose adjustments:
• Any current infection or fever.
• Kidney disease (a reduced dose of 0.16 mg/kg is required for patients with moderate to severe renal impairment).
• Leukemia

Drug Interactions:

Before receiving Mozobil, discuss all potential risks and interactions with your doctor or pharmacist. For complete information, please refer to the product monograph at https://pdf.hres.ca/dpd_pm/00040090.PDF.

Provide your doctor with a complete list of all your medications, including prescriptions, over-the-counter (OTC) drugs, vitamins, herbal supplements, recreational drugs, and any significant dietary changes, as these may interact with Mozobil.

No significant drug-drug interactions have been identified with plerixafor in clinical studies. However, review all current medications with your healthcare team before receiving Mozobil.

Pregnancy and Breastfeeding:

Inform your doctor if you are pregnant or planning to become pregnant. Mozobil may cause harm to an unborn baby. Women of childbearing potential should use effective contraception while receiving Mozobil. Animal studies have shown evidence of fetal harm. Mozobil should not be used during pregnancy unless clearly necessary. Consult your doctor to weigh the benefits and risks of this medicine before using it while nursing. It is not known whether plerixafor is excreted in breast milk; breastfeeding is not recommended while receiving Mozobil. Discuss the risks and benefits with your doctor.

Use in Children:

Mozobil has been studied in children and may be used in pediatric patients in certain transplantation settings under specialist supervision. Children aged 1 to less than 18 years old can receive Mozobil for up to 3 consecutive days. Dosing in children is weight-based and determined by a hematologist.

Frequently Asked Questions about Mozobil at Canada Pharmacy Online

Why is Mozobil more affordable in Canada than in the United States?

Prescription drug prices, including Mozobil, are generally lower in Canada than in the U.S. due to a combination of factors, primarily government price regulations, differing market dynamics, and other economic considerations. In Canada, provincial and federal governments negotiate drug prices with pharmaceutical companies, which often results in lower prices than in the U.S., where market forces play a more significant role. For more information, see the FAQs on Prescription Drug Importation from the Kaiser Family Foundation (KFF): https://www.kff.org/health-costs/issue-brief/faqs-on-prescription-drug-importation/

How much is the shipping?

Our shipping fee is a flat rate of $10.00 per order. Our pharmacy is dedicated to offering you the lowest prices on high-quality products.

How do I place an order with your pharmacy?

Ordering from us is very simple. You can purchase online or call Customer Service at 1.866.920.3784; for more information or to learn about the ordering process, visit our How to Order page.

Can I buy Mozobil from you over the counter?

No, Mozobil requires a valid prescription from your doctor. We do not sell this product without a valid prescription.

Do you ship to the United States?

Yes, we do. It usually takes between 7 and 18 business days to receive your order from our pharmacy.

Is there a generic for Mozobil?

No, the generic alternative is currently unavailable (at this pharmacy).

Blog Post:

Why is Fatty Liver Disease on The Rise?

Latest News:

Research shows weight-loss drugs may also reduce cancer risk (study published on June 19, 2026)

Similar Drugs in the category of Cancer Medications:

Arimidex Nolvadex Zofran Gleevec Femara

The information on this page is sourced from independent third parties contracted by CanadaPharmacyOnline. While we cannot guarantee its medical accuracy, we strongly recommend consulting a healthcare professional for personalized advice regarding medications or medical conditions.

Reviews From Real Customers